HC Wainwright Analysts Raise Earnings Estimates for CASI

CASI Pharmaceuticals Inc. (NASDAQ:CASI) – Equities research analysts at HC Wainwright boosted their Q3 2025 earnings estimates for shares of CASI Pharmaceuticals in a research note issued on Wednesday, September 3rd. HC Wainwright analyst S. Lee now forecasts that the biotechnology company will post earnings per share of ($0.40) for the quarter, up from their prior forecast of ($0.51). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($2.31) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($1.41) EPS, FY2028 earnings at ($1.39) EPS and FY2029 earnings at ($0.98) EPS.

Separately, Wall Street Zen started coverage on shares of CASI Pharmaceuticals in a report on Thursday, May 22nd. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, CASI Pharmaceuticals currently has an average rating of “Buy” and an average target price of $4.00.

CASI Pharmaceuticals Stock Up 2.6%

Shares of CASI Pharmaceuticals stock opened at $2.34 on Friday. The firm has a market cap of $28.78 million, a PE ratio of -0.81 and a beta of 0.77. CASI Pharmaceuticals has a 12-month low of $1.09 and a 12-month high of $7.67. The company’s fifty day simple moving average is $1.74 and its two-hundred day simple moving average is $1.90.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Friday, August 29th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.39). The firm had revenue of $4.18 million during the quarter, compared to the consensus estimate of $6.28 million. CASI Pharmaceuticals had a negative return on equity of 1,844.13% and a negative net margin of 148.55%.

Institutional Investors Weigh In On CASI Pharmaceuticals

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Woodline Partners LP boosted its holdings in shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) by 64.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,365 shares of the biotechnology company’s stock after acquiring an additional 64,675 shares during the period. Woodline Partners LP owned 1.34% of CASI Pharmaceuticals worth $355,000 at the end of the most recent reporting period. 22.23% of the stock is currently owned by institutional investors.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.